End Stage Renal Disease Clinical Trial
— SODIAHOfficial title:
Comparison of Individualized Sodium Management Versus Standard Treatment in Hemodialysis
The SODIAH study is designed with the aim to assess the impact of isonatremic dialysis on interdialytic weight gain, fluid status, intradialytic hemodynamic stability, and incidence of intradialytic morbid events in dialysis patients. The study will be comparing the Na management option on the 6008 HD dialysis machines with the same machine without the Na management option turned on. Relevant performance and clinical data will be collected as well as information on patients' quality of life and wellbeing.
Status | Not yet recruiting |
Enrollment | 130 |
Est. completion date | December 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: General: - Informed consent signed and dated by study patient and authorized physician - Minimum age of 18 years - The patient is legally competent and able to understand the nature, risks, meaning, and consequences of the clinical trial and can subsequently declare her/his consent for participation in the clinical trial - Patients with a chronic kidney disease stage 5D (end stage renal disease with a glomerular filtration rate of 15 ml/min or less) on dialysis as extracorporeal renal replacement therapy. Study-specific: - Patients on dialysis (HD/HDF), at least 4h treatment time thrice weekly = 3 months using a standard dialysate with a prescribed sodium concentration of 136 mmol/L - Anuric patients (<300mL/d; 1 measurement within last 4 weeks) - Patient fulfils one of the four following criteria: interdialytic weight gain over 4% of dry weight (mean value during run-in period) OR pre-dialytic systolic blood pressure over 180 mmHg (mean value during run-in period) OR intradialytic morbid events (hypotension, hypertension, cramps, headache) in at least three sessions during run-in period OR volume overload according to BCM (FO =2.5 L pre-dialysis or relative FO pre-dialysis =15% for men and =13% for women; one measurement during run-in period) - Patients with a diffusive Na load of at least 1 mmoL/(L TBW) or 0.06g NaCl/(L TBW) (mean value during the run-in period). Exclusion Criteria: General: - Any conditions which could interfere with the patient's ability to comply with the study - Patient is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations - In case of female patients: pregnancy (pregnancy test will be conducted at start and end of study with female patients aged =55 years) or lactation period - Participation in an interventional clinical study during the preceding 30 days - Previous participation in the same study Study-specific: - Patients treated with individualized sodium management over the last 3 months - Severe hypoalbuminemia (=30 g/L; 1 measurement within last 4 weeks) - Hypernatremia (pre-dialytic plasma sodium concentration =145mmol/L; 1 measurement within last 4 weeks) - Uncontrolled diabetic patients with glycated hemoglobin (HbA1C) >8%; 1 measurement within last 4 weeks - Impossible reliable measurement of the different compartments by bioimpedance due to lower limb amputation or wearing of a unipolar pacemaker or metallic prostheses - Life expectancy less than 6 months - ONLINEplus HF treatments/hemofiltration treatments - Single-needle treatments - Dry weight < 40kg - Active or chronic infections (HIV, SARS-CoV-2, HBV, HCV) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fresenius Medical Care Deutschland GmbH |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Interdialytic weight gain | Evaluation of the impact of sodium zero-diffusive dialysis on interdialytic weight gain will be analyzed in kg and % of dry weight | 12 weeks after start of study | |
Primary | Intradialytic hemodynamic stability | Evaluation of the impact of sodium zero-diffusive dialysis on intradialytic hemodynamic stability will be analyzed based on frequency of intradialytic hypotensive episodes | 12 weeks after start of study | |
Primary | Intradialytic hemodynamic stability | Evaluation of the impact of sodium zero-diffusive dialysis on intradialytic hemodynamic stability will be analyzed based on frequency of intradialytic hypertensive episodes | 12 weeks after start of study | |
Primary | Intradialytic morbid events | Evaluation of the impact of sodium zero-diffusive dialysis on the frequency of intradialytic morbid events will be analyzed | 12 weeks after start of study | |
Primary | Fluid status | Evaluation of the impact of sodium zero-diffusive dialysis on fluid status will be analyzed with regard to overhydration (L) | 12 weeks after start of study | |
Primary | Fluid status | Evaluation of the impact of sodium zero-diffusive dialysis on fluid status will be analyzed with regard to dry weight (kg) | 12 weeks after start of study | |
Secondary | PRO: Thirst feeling | Evaluation of thirst feeling will be assessed via the Dialysis Thirst Inventory | 12 weeks after start of study | |
Secondary | PRO: Thirst feeling | Evaluation of thirst feeling will be assessed via the Xerostomia Inventory | 12 weeks after start of study | |
Secondary | PRO: Fatigue | Evaluation of fatigue will be assessed via the CONVINCE Dialysis Fatigue Scale (CFDS-10) | 12 weeks after start of study | |
Secondary | PRO: Hypotensive episodes | Evaluation of hypotensive episodes will be assessed via the CONVINCE intradialytic symptoms (IDS) Scale - hypotensive episodes items | 12 weeks after start of study | |
Secondary | PRO: HRQOL | Evaluation of health related quality of life (HRQOL) will be assessed using the validated Kidney Disease Quality of Life (KDQOL) survey KDQOL-36 | 12 weeks after start of study | |
Secondary | PRO: Health status | Evaluation of health status will be assessed via the validated EQ-5D-5L survey by EuroQol group | 12 weeks after start of study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04076488 -
Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases
|
N/A | |
Completed |
NCT03289650 -
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
|
Phase 3 | |
Completed |
NCT04042324 -
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01242904 -
Use of a Bimodal Solution for Peritoneal Dialysis
|
Phase 2 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03257410 -
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A | |
Withdrawn |
NCT02130817 -
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
|
Phase 4 | |
Completed |
NCT05540457 -
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
|
N/A | |
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Recruiting |
NCT02176434 -
Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease
|
N/A | |
Active, not recruiting |
NCT02581449 -
Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
|
Phase 2 | |
Completed |
NCT02215655 -
Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence
|
N/A | |
Completed |
NCT02830490 -
Reliability of Functional Measures in Hemodialysis Patient.
|
N/A | |
Completed |
NCT02832440 -
Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis
|
N/A | |
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Completed |
NCT02832466 -
Quantifying the Deterioration of Physical Function in Renal Patients
|
N/A | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A |